Tags : Helsinn


BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib

Shots: BridgeBio to receive ~$2.45B+ including ~$100M in up front, regulatory and commercial milestones along with royalties on net sales of Infigratinib from Helsinn Group. The agreement is expected to close in Q2’21 Helsinn to co-commercialize infigratinib in oncology and other indications except for skeletal dysplasia indications in the US and will equally share profits […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (September 02 – 06, 2019)

1.Roche’s Tecentriq + Chemotherapy Receives EC’s Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer Published: Sept 06, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Receives, EC, Approval, Initial Treatment, Extensive Stage Small Cell Lung Cancer 2. OncoCyte to Acquire Razor Genomics for the Expansion of its Capabilities in Early-Stage Lung Cancer Published: Sept 05, 2019 […]Read More


Helsinn Enters into an Exclusive Distribution and License Agreement with

Shots: Blanver to register, promote, distribute & commercialize Pracinostat in Brazil while Varifarma to get rights in Argentina, Bolivia, Chile, Colombia, Ecuador, Paraguay, Peru, and Uruguay. Helsinn to retain rights all international developments including clinical activities & supply of Pracinostat In 2016, MEI Pharma granted global rights of Pracinostat to Helsinn and a right to […]Read More